(NASDAQ: AXSM) Axsome Therapeutics's forecast annual revenue growth rate of 51.31% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.7%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.79%.
Axsome Therapeutics's revenue in 2026 is $638,496,000.On average, 22 Wall Street analysts forecast AXSM's revenue for 2026 to be $51,664,821,890, with the lowest AXSM revenue forecast at $45,563,257,578, and the highest AXSM revenue forecast at $56,780,150,790. On average, 22 Wall Street analysts forecast AXSM's revenue for 2027 to be $80,310,663,730, with the lowest AXSM revenue forecast at $61,588,559,956, and the highest AXSM revenue forecast at $98,828,154,348.
In 2028, AXSM is forecast to generate $114,174,141,048 in revenue, with the lowest revenue forecast at $78,571,451,904 and the highest revenue forecast at $189,113,709,433.